Diabetic Ketoacidosis News and Research

RSS

Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.

Adults as likely to develop type 1 diabetes as children, research finds

Type 1 diabetes is not predominantly a 'disease of childhood' as previously believed, but is similarly prevalent in adults, new research published in the Lancet Diabetes & Endocrinology shows.

30 Nov 2017

EKF Diagnostics and Ortho Clinical Diagnostics collaborate on a new diabetic ketoacidosis assay

Ortho Clinical Diagnostics and EKF announce an agreement that allows Ortho customers to access to Beta-Hydroxybutyrate assay.

From EKF Diagnostics 12 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes

A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.

13 Sep 2017

New research aims to generate in vitro vascularized pancreatic islets from hPSCs

Tiny packets of cells called islets throughout the pancreas allow the organ to produce insulin. Type 1 diabetes -- also known as juvenile diabetes - tricks the immune system into destroying these islets.

23 Aug 2017

3U researchers discover biological marker that could predict development of Type 1 diabetes

A significant finding has been made by the 3U Diabetes Consortium, of Dublin City University, Maynooth University and the Royal College of Surgeons in Ireland, which has the potential to contribute to the identification of biological markers that predict the development of Type 1 diabetes, a chronic autoimmune disease.

27 Mar 2017

Study finds reduction in HbA1c levels with in-home use of hybrid closed-loop insulin delivery system

A pivotal registration trial to evaluate in-home use of the Medtronic MiniMed(r) 670G hybrid closed-loop insulin delivery system over 3 months showed a significant reduction in HbA1c levels for both adolescents and adults with type 1 diabetes.

13 Feb 2017

New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

2 Dec 2016

FDA approves Medtronic's ‘artificial pancreas’ for type 1 diabetes patients

The U.S. Food and Drug Administration today approved Medtronic's MiniMed 670G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes.

28 Sep 2016

Detecting diabetes’ deadly ketones

A simple, hand-held breath testing device that detects deadly ketones has been developed by University of Sydney researchers. The device could mean an end to finger-prick blood tests for diabetes patients.

26 Aug 2016

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

A combination of three medications—dapagliflozin, liraglutide and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Aug 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.

From Novo Nordisk 26 Sep 2015

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events.

20 Aug 2015

Integrated treatment required for diabetes-eating disorder combination

As they reach their teens, many with type 1 diabetes discover that the disease provides a secret weapon for losing weight. By restricting or reducing the amount of insulin they inject, they can eat just about anything they want and control their weight.

3 Aug 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015